Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

NCT05112536 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer
Breast Cancer

Interventions

DRUG: Trilaciclib
DRUG: Cylophosphamide
DRUG: Doxorubicin
DRUG: Paclitaxel
DRUG: Carboplatin (Investigator discretion)
BIOLOGICAL: Pembrolizumab (Investigator discretion)

Sponsor

G1 Therapeutics, Inc.